Hair loss drug showdown: tofacitinib vs methotrexate in new trial
NCT ID NCT07406204
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two oral medications—tofacitinib and methotrexate—for treating severe alopecia areata, an autoimmune condition causing hair loss. 78 adults aged 18-60 with severe scalp or total body hair loss will take one of the drugs for 12 weeks. The main goal is to see which medicine leads to more hair regrowth, measured by a standard hair loss score.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tofacitinib and methotrexate
What this could lead to
If successful, this could show that tofacitinib is a more effective option than methotrexate for regrowing hair in severe alopecia areata.
What could go wrong
This is a small, early-stage trial with only 78 participants and a short 12-week treatment period. Results may not apply to everyone, and both drugs have side effects like infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••